Corbus Pharmaceuticals (CRBP) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 24.3% versus a loss of 60.7%. Over five years, CRBP leads with a -82.8% price change compared with -96.4% for OKUR. Corbus Pharmaceuticals is the larger company by market cap ($101.9 million vs $93.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | OKUR |
|---|---|---|
| Share price | $5.27 | $2.30 |
| Market cap | $101.93M | $93.14M |
| 1-day change | -4.01% | -2.13% |
| YTD return | -35.26% | -20.69% |
| 1-year return | -60.73% | -24.34% |
| 5-year return | -82.78% | -96.43% |
| EPS (TTM) | $-6.11 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $5.38 |
| 52-week low | $5.13 | $2.13 |
| Distance from 52-week high | -74.37% | -57.25% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +545.73% | +573.91% |
| Average volume | 756.54K | 216.96K |
| Shares outstanding | 19.34M | 40.50M |
| Employees | 36 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKUR has outperformed CRBP by 36.4 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
CRBP vs OKUR FAQ
Which is bigger, Corbus Pharmaceuticals or OnKure Therapeutics?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $101.93M compared with $93.14M for OnKure Therapeutics (OKUR).
Which stock has performed better over the past year, CRBP or OKUR?
OKUR returned -24.34% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.